ELGX Endologix Inc

Endologix, Inc. (Nasdaq:ELGX) today announced U.S. Food and Drug Administration (FDA) approval of the PMA supplement for its Powerlink XL� System, which includes new suprarenal stent grafts as well as the new Powerlink XL stent graft. This approval substantially broadens the Company�s treatment indications for the Powerlink System, which is used in the minimally invasive treatment of abdominal aortic aneurysms (AAA). The Powerlink XL System was evaluated in an IDE clinical study and approved for the treatment of AAA patients with proximal aortic necks between 23 millimeters and 32 millimeters. �This approval is important for patients with AAA, because the Powerlink XL System offers the lowest profile catheter of all commercially available devices in the U.S. indicated for aortic necks greater than 26 millimeters,� said John McDermott, Endologix President and CEO. The low profile Powerlink XL System expands the market for AAA procedures by enabling treatment in patients with limited or difficult vascular access. In addition to its low profile, the Powerlink and Powerlink XL Systems are the only commercially available AAA devices with proximal extensions offered in both infrarenal and suprarenal configurations. By providing both design options, Endologix enables physicians to choose the most optimal device to treat a wide range of patient anatomies. Furthermore, the Powerlink XL opens a new market segment to Endologix, as approximately 15% of endovascular AAA procedures are performed in patients with aortic necks greater than 26 millimeters. �We already have a reputation for providing minimally invasive solutions for AAA patients with complex anatomies and this approval further strengthens our position,� added Mr. McDermott. �We look forward to launching this innovative technology and expanding the treatment options for AAA patients in the U.S.� About Endologix Endologix, Inc. develops and manufactures minimally invasive treatments for vascular diseases. Endologix's Powerlink System is an endoluminal stent graft for treating abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix�s Web site at www.endologix.com. Except for historical information contained herein, this news release contains forward-looking statements relating to the continued growth of Endologix�s business and an increasing share of the endovascular AAA market, the accuracy of which are necessarily subject to risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Endologix. The Company undertakes no obligation to update its forward looking statements. Please refer to the Company�s Annual Report on Form 10-K for the year ended December 31, 2007, and the Company�s other filings with the Securities and Exchange Commission, for more detailed information regarding these risks and other factors that may cause actual results to differ materially from those expressed or implied.